News

The treatment was tested in a trial of 7,513 patients hospitalized and susceptible to the condition.

A new retrospective study has determined that treating intravenous-drug users with HCV with direct acting antivirals in outpatient programs provides highly successful outcomes.

The drug is an investigational treatment for adults with HCV.

Stephen Krieger, MD, explains how the monoclonal antibody changed the state of MS treatment.

Certain microbial strains persisted in donor recipients for as long as 2 years after an FMT.

The subcutaneous treatment can be used for HAE attacks at home.

Navigating the adverse effects, and potential benefits, for the neurological condition's treatments.

An epidemiologist shares his knowledge about Clostridium difficile prevention and control.

The Republican Senate repeal to the Affordable Care Act came 2 months after the House passed the American Health Care Act.

The drug reduced cardiovascular risk in people with prior heart attack and inflammatory atherosclerosis.

Novo Nordisk seeks broad primary prevention claim, EMDAC recommends drug for patients with established CV.

The anti-CGRP monoclonal antibody showed long-term efficacy versus placebo in migraine pain impact.

The CANVAS results yield promise against cardiovascular events, but a risk of amputations.

Access to a transition coordinator benefited youths with T1D during their transition period.

William Polonsky, PhD, CDE, explains where more benefits lie in T2D patients using the monitoring devices.

The mixed amphetaminies salts formulation included 16 clinical trials results in its application.

The drug is comparable to aflibercept for nAMD, according to Novartis.

High bacterial load, gender, and age are predictors of poor outcomes in C. difficile.

Researchers are working to identify T1D patients earlier, prevent mishaps before they occur.

The once-daily treatment is an oral formulation of central nervous system stimulant methylphenidate.

Maternal use of lithium in the first trimester raises risk of cardiac defects to the fetus.

A new meta-analysis found that 31 percent of patients in antidepressant treatment trials for persistent depressive disorder (PDD) responded to placebo and 57 percent reported adverse (nocebo) effects to them.

The test allows for rapid, accurate testing of serum samples with results in 30 minutes.

Bipolar disorder patients with Alzheimer's have a 2.3-fold increased chance of having been diagnosed with HCV.

The drug is available for injection and in oral tablets.

The opioid treatment program's studies yielded positive results.

Manufacturer Rigel Pharmaceuticals expects an FDA decision by April, 2018.

Study shows that GRT is useful for identifying effective alternative treatments.